Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for Gossamer Bio (GOSS) over the last 4 years, with Q3 2025 value amounting to $2.7 million.

  • Gossamer Bio's Share-based Compensation fell 4494.01% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.6 million, marking a year-over-year decrease of 4179.66%. This contributed to the annual value of $20.6 million for FY2024, which is 2769.83% down from last year.
  • Gossamer Bio's Share-based Compensation amounted to $2.7 million in Q3 2025, which was down 4494.01% from $2.6 million recorded in Q2 2025.
  • Gossamer Bio's 5-year Share-based Compensation high stood at $11.4 million for Q4 2022, and its period low was $2.4 million during Q1 2025.
  • In the last 4 years, Gossamer Bio's Share-based Compensation had a median value of $6.0 million in 2023 and averaged $6.6 million.
  • In the last 5 years, Gossamer Bio's Share-based Compensation crashed by 1768.9% in 2024 and then crashed by 5861.3% in 2025.
  • Over the past 4 years, Gossamer Bio's Share-based Compensation (Quarter) stood at $11.4 million in 2022, then plummeted by 47.31% to $6.0 million in 2023, then fell by 17.69% to $5.0 million in 2024, then plummeted by 46.3% to $2.7 million in 2025.
  • Its Share-based Compensation was $2.7 million in Q3 2025, compared to $2.6 million in Q2 2025 and $2.4 million in Q1 2025.